Molbio Diagnostics Invests $30 Million in OptraSCAN to Revolutionize Digital Pathology

BioNTech Acquires Chinese Oncology Firm Biotheus for $950M

The Care and Protection of Children Trust

CPCT Launches Groundbreaking Initiative to Provide Lifelong Free Treatment for Children with Spinal Muscular Atrophy (SMA) in Karnataka

Early Comprehensive Genomic Profiling Improves Cancer Treatment Outcomes, Study Shows

EMA Reverses Decision, Recommends Limited Approval for Eisai and Biogen’s Alzheimer’s Drug Leqembi

Exact Sciences Unveils Advances in Multi-Cancer Early Detection with Cancerguard™ Test

MSD and LaNova Medicines Enter Exclusive Global License Agreement for Novel Cancer Therapy, LM-299

Promising CAR T Cell Therapies from BMS and Cabaletta Bio Show Potential for Durable Remission in Severe Lupus

FDA Grants Accelerated Approval to PTC Therapeutics' KEBILIDI™, the First Gene Therapy for AADC Deficiency in the U.S.

Association for Molecular Pathology Publishes Joint Consensus Report on SARS-CoV-2 Genomic Surveillance for Hospitals and Public Health Laboratories

Philips India Unveils Advanced Azurion Imaging System to Revolutionize Cardiac and Neurovascular Care

Tempus AI Study Highlights Benefits of Dual RNA and DNA Sequencing for Advanced Lung Cancer

Ontada and Datavant Partner to Expand Access to Real-World Oncology Data for Accelerated Cancer Innovation

Tempus AI and Flatiron Health Partner to Integrate Genomic Testing into OncoEMR for Enhanced Oncology Care

Flare Therapeutics and Roche Forge Strategic Partnership to Discover Precision Oncology Therapies Targeting Transcription Factors

Home
/
update
/
details

Redcliffe Labs Introduces Gut Microbiome and HealthEx Tests to Enhance Preventive Healthcare

NextEdge Admin

20 Sep 2024

2 min 47 sec

Redcliffe Labs has expanded its diagnostic services with the launch of two specialized tests: the Gut Microbiome Test and HealthEx. Available across 220+ cities in India, these tests aim to enhance preventive healthcare by empowering individuals with personalized health insights.

As lifestyle and non-communicable diseases rise across the country, Redcliffe Labs focuses on early detection to help individuals take control of their health. The Gut Microbiome Test, a non-invasive tool, offers a comprehensive analysis of gut health, which is influenced by factors such as diet, genetics, and lifestyle. It provides insights into immune function, hormonal balance, cognitive performance, and metabolic health, addressing issues like obesity, diabetes, and cardiac health. The test also identifies conditions related to auto-immunity, dermatology, and mental health, and includes a 12-week personalized nutrition plan along with expert counseling to support gut health restoration.

The HealthEx test evaluates an individual’s DNA to identify potential health risks associated with lifestyle, diet, and genetics. This advanced blood test offers personalized recommendations for diet, fitness, cardiac health, sleep quality, and cancer risk. Both tests aim to help individuals make informed health decisions and adopt proactive lifestyle changes.

Aditya Kandoi, Founder and CEO of Redcliffe Labs, emphasized the importance of early detection and personalized care in achieving better health outcomes. Dr. Geetanjali Gupta, Director of Technical Operations & Quality Assurance, highlighted how these tests help monitor vital health markers, enabling healthcare providers to optimize treatment plans.

Both tests are available through Redcliffe Labs’ app, website, and collection centers, offering a seamless experience. The Gut Microbiome Test is for individuals aged six and above, while HealthEx is available for those over five years old, reinforcing Redcliffe Labs’ commitment to preventive healthcare.